Quintiles has acquired VCG & Associates and VCG BIO. The addition of VCG strengthens Quintiles’ comprehensive commercial services in sales and brand solutions, product solutions, product distribution and market access.

VCG develops strategic healthcare marketing initiatives to address the challenges surrounding U.S. pharmaceutical market entry. It focuses on biopharma companies that need supplemental resources to maximize commercial opportunities. VCG brings experience in the areas of market access, distribution and reimbursement implementation.

“VCG complements our solutions and capabilities within both our commercial and consulting divisions with emerging biopharma, companies looking to establish a commercial presence in the U.S., and drug development companies entering the commercial space for the first time,” said Rich Pilnik, president, global commercial solutions.

VCG has experience across numerous therapeutic areas and device markets, contacts throughout the healthcare industry, access to managed care organizations and government payers, and special services with distribution and pricing analysis for commercial entry.

“We have worked closely with Quintiles for the past several years, and this acquisition is a natural step that allows both organizations to serve our customers with specialized commercialization offerings. VCG will continue to provide our customers the same high level of service from our talented employees and trusted business operations and processes, while drawing upon Quintiles’ complementary expertise and services,” VCG co-founder and managing partner Brad Fleahman said.